2013
Adoptively transferred TRAIL+ T cells suppress GVHD and augment antitumor activity
Ghosh A, Dogan Y, Moroz M, Holland A, Yim N, Rao U, Young L, Tannenbaum D, Masih D, Velardi E, Tsai J, Jenq R, Penack O, Hanash A, Smith O, Piersanti K, Lezcano C, Murphy G, Liu C, Palomba M, Sauer M, Sadelain M, Ponomarev V, van den Brink M. Adoptively transferred TRAIL+ T cells suppress GVHD and augment antitumor activity. Journal Of Clinical Investigation 2013, 123: 2654-2662. PMID: 23676461, PMCID: PMC3668849, DOI: 10.1172/jci66301.Peer-Reviewed Original ResearchMeSH KeywordsAdoptive TransferAnimalsAntigen-Presenting CellsCell Line, TumorCytotoxicity, ImmunologicGraft RejectionGraft vs Host DiseaseHEK293 CellsHumansImmunotherapy, AdoptiveLeukemia, Lymphocytic, Chronic, B-CellMiceMice, Inbred BALB CMice, Inbred C57BLNeoplasm TransplantationT-LymphocytesTNF-Related Apoptosis-Inducing LigandConceptsGVT responseT cellsAllo-HSCTAllogeneic hematopoietic stem cell transplantationHematopoietic stem cell transplantationCellular therapyAbsence of GVHDDR5-dependent mannerDonor T cellsAlloreactive T cellsStem cell transplantationChronic lymphocytic leukemia cellsPrecursor T cellsThird-party donorsLymphocytic leukemia cellsApoptosis-inducing ligandGVT activityHost diseaseCell transplantationCurative potentialTumor responseGVHDCertain malignanciesMouse modelHuman leukemia cell lines
2012
Repertoire Enhancement with Adoptively Transferred Female Lymphocytes Controls the Growth of Pre-Implanted Murine Prostate Cancer
Jenq R, Curran M, Goldberg G, Liu C, Allison J, van den Brink M. Repertoire Enhancement with Adoptively Transferred Female Lymphocytes Controls the Growth of Pre-Implanted Murine Prostate Cancer. PLOS ONE 2012, 7: e35222. PMID: 22493742, PMCID: PMC3320876, DOI: 10.1371/journal.pone.0035222.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinomaAdultAnimalsAntigens, NeoplasmCD4-Positive T-LymphocytesCD8-Positive T-LymphocytesDEAD-box RNA HelicasesFemaleGraft vs Host DiseaseHumansImmunotherapy, AdoptiveLymphocyte CountMaleMiceMinor Histocompatibility AntigensNeoplasm TransplantationProstatic NeoplasmsSex FactorsWhole-Body IrradiationConceptsCD4 T cellsT cellsProstatic adenocarcinoma cellsAdoptive transferProstate cancerEffective anti-tumor immune responseCancer-reactive T cellsCD8 T cell responsesHigh-affinity T cellsPotential tumor rejection antigensTRAMP-C2 tumor cellsAnti-tumor immune responseAdenocarcinoma cellsExacerbation of graftPresence of CD25Female lymphocytesRegulatory T cellsAdoptive transfer modelReactive T cellsT cell responsesT cell repertoireMurine prostate cancerProstate cancer antigenAdult male hostsTumor rejection antigens
2002
Donor leukocyte infusion from immunized donors increases tumor vaccine efficacy after allogeneic bone marrow transplantation.
Teshima T, Liu C, Lowler K, Dranoff G, Ferrara J. Donor leukocyte infusion from immunized donors increases tumor vaccine efficacy after allogeneic bone marrow transplantation. Cancer Research 2002, 62: 796-800. PMID: 11830535.Peer-Reviewed Original ResearchConceptsAllogeneic bone marrow transplantationBone marrow transplantationDonor leukocyte infusionImmunization of donorsLeukocyte infusionMarrow transplantationTumor vaccinesT cellsT cell-depleted allogeneic bone marrow transplantationTumor-specific T-cell responsesTumor vaccine efficacyDonor T cellsRecurrence of malignancyPotent antitumor immunityT cell responsesAnalysis of splenocytesT cell proliferationGranulocyte-macrophage colony-stimulating factorPotent T-cell proliferationNovel treatment strategiesColony-stimulating factorSpecific antitumor activityB16 melanoma cellsBeneficial graftHarmful graft